RxDoctor Payments Data

Joseph Puma, DO

Interventional Cardiology · New York, NYNPI 1982604914

Payments from drug & device makers

$52,079in general payments, 2019–2025

Across 56 payments — averaging $929.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$20K
  • Siemens Medical Solutions USA, Inc.$15K
  • Cardiovascular Systems Inc.$15K
  • Medtronic$285
  • Angiodynamics, Inc.$241
  • Heartflow, Inc.$218
  • plus $489 from 8 others

What the payments were for

  • Consulting fees$12,53428%
  • Speaking & faculty fees$28,89064%
  • Travel & lodging$9582%
  • Food & beverage$2,7976%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,079 in reported general payments places this provider in the 70th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$598,517
Medicare patients
301
Services billed
3,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$75,808
Repatha SureclickEvolocumab93$74,625
EntrestoSacubitril/Valsartan48$71,496
EliquisApixaban65$70,038
XareltoRivaroxaban41$34,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$26,708
MounjaroTirzepatide17$19,331
CreonLipase/Protease/Amylase15$15,223
JardianceEmpagliflozin17$14,519
Diclofenac Sodium72$12,055
JanumetSitagliptin Phos/Metformin Hcl15$11,383
LinzessLinaclotide16$9,341
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,258
VascepaIcosapent Ethyl23$9,253
Dexlansoprazole DrDexlansoprazole31$8,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Brilinta$25$15,35628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →